<div><div></div><div>NexGel secured $1.21 million in a private placement of unsecured convertible promissory notes and warrants with accredited investors, setting an initial note conversion price of $0.60 per share and a warrant exercise price of $0.80 for 1,008,334 shares, with warrants expiring five years from issuance. Proceeds will support working capital, and a significant portion was purchased by company affiliates. Concurrently, NexGel agreed to register the resale of the underlying shares, committing to file within 75 days and target effectiveness within 150 days, enhancing investor liquidity.Agreement 1: NexGel Raises $1.21 Million Via Convertible Notes and Warrants; $0.60 Conversion, $0.80 Exercise<ul><li>Agreement type: Securities Purchase Agreement for unsecured convertible notes and warrants (private placement)</li><li>Counterparty: Accredited Investors</li><li>Signed / Effective: May 11 2026 / same</li><li>Duration / Termination: Warrants: 5 years; Notes: N/A</li><li>Reason: Strengthen liquidity and fund working capital</li></ul>Agreement 2: NexGel Agrees to Register Resale of Note and Warrant Shares Under New Registration Rights Deal<ul><li>Agreement type: Registration Rights Agreement for resale of note and warrant shares</li><li>Counterparty: Accredited Investors</li><li>Signed / Effective: May 11 2026 / same</li><li>Duration / Termination: N/A</li><li>Reason: Provide resale liquidity to investors</li></ul>Original SEC Filing: NEXGEL, INC. [ NXGL ] - 8-K - May. 15, 2026<section>Disclaimer<div>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</div></section></div></div>

NXGL

SBIO

LABU

NexGel raised $1.21 million through a private placement of unsecured convertible notes and warrants, with a conversion price of $0.60 per share and a warrant exercise price of $0.80. The funds will support working capital, with a significant portion purchased by affiliates. NexGel also agreed to register the resale of underlying shares, enhancing investor liquidity.

TradingView

Nexgel

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

iShares US Medical Devices

ALPS Medical Breakthrough

iShares Biotechnology ETF

VanEck Biotech ETF

SPDR S&P Health Equip

Direxion S&P Biotech Bull 3X

NEXGEL INC C/WTS 27/12/2026 (TO PUR COM)

NexGel Raises $1.21 Million Via Convertible Notes and Warrants; $0.60 Conversion, $0.80 Exercise